CCL18 and myeloid sarcoma: Our findings in patients are coherent with previous data: (i) PC and CCL18 levels have been positively associated with neurodegeneration (5, 10), (ii) the proteomic profiles within chronic active plaques have detected the presence of the PC inhibitor (26), which binds activated PC, and (iii) high CCL18 gene expression has been found in the rim of chronic active MS lesions (27).